Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2012

01-09-2012 | Article

Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models

Authors: H. Low, A. Hoang, J. Forbes, M. Thomas, J. G. Lyons, P. Nestel, L. A. Bach, D. Sviridov

Published in: Diabetologia | Issue 9/2012

Login to get access

Abstract

Aims/hypothesis

We investigated the contribution of AGEs to the impairment of reverse cholesterol transport (RCT) variables in diabetic individuals and in two animal models of diabetic obesity and of renal impairment.

Methods

The capacity of plasma and HDL from 26 individuals with moderately controlled type 2 diabetes to support cholesterol efflux was compared with 26 age- and sex-matched individuals without diabetes. We also compared the rates of RCT in vivo in two animal models: db/db mice and mice with chronic renal failure.

Results

Diabetic individuals had characteristic dyslipidaemia and higher levels of plasma AGEs. The capacity of whole plasma, ApoB-depleted plasma and isolated HDL to support cholesterol efflux was greater for diabetic patients compared with controls despite their lower HDL-cholesterol levels. The capacity of plasma to support cholesterol efflux correlated with plasma levels of cholesteryl ester transfer protein and levels of ApoB, but not with levels of AGE. RCT was severely impaired in db/db mice despite elevated HDL-cholesterol levels and no change in AGE concentration, whereas RCT in uraemic mice was unaffected despite elevated AGE levels.

Conclusions/interpretation

AGEs are unlikely to contribute significantly to the impairment of RCT in type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef
2.
Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581PubMedCrossRef
3.
Goldberg IJ (2004) Why does diabetes increase atherosclerosis? I don’t know! J Clin Invest 114:613–615PubMed
4.
Berthezene F (1996) Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 124(Suppl):S39–S42PubMedCrossRef
5.
Kappelle PJ, de Boer JF, Perton FG et al (2012) Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 42:487–495PubMedCrossRef
6.
Riemens S, van Tol A, Sluiter W, Dullaart R (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79PubMedCrossRef
7.
Griffin E, Re A, Hamel N et al (2001) A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 7:840–846PubMedCrossRef
8.
Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, Horiuchi S (2003) Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 10:1–6PubMedCrossRef
9.
Oram JF, Vaughan AM (2006) ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 99:1031–1043PubMedCrossRef
10.
Autran D, Attia N, Dedecjus M, Durlach V, Girard-Globa A (2000) Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment. Atherosclerosis 153:453–460PubMedCrossRef
11.
Syvanne M, Castro G, Dengremont C et al (1996) Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:LpAII particles and phospholipid transfer protein. Atherosclerosis 127:245–253PubMedCrossRef
12.
Nestel P, Hoang A, Sviridov D, Straznicky N (2012) Cholesterol efflux from macrophages is influenced differentially by plasmas from overweight insulin-sensitive and -resistant subjects. Int J Obes (Lond) 36:407–413CrossRef
13.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
14.
Lapolla A, Brioschi M, Banfi C et al (2007) Nonenzymatically glycated lipoprotein Apo-AI in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci 26:295–299
15.
Hoang A, Murphy AJ, Coughlan MT et al (2007) Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50:1770–1779PubMedCrossRef
16.
Nobecourt E, Davies MJ, Brown BE et al (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50:643–653PubMedCrossRef
17.
Duell PB, Oram JF, Bierman EL (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40:377–384PubMedCrossRef
18.
Hoang A, Drew BG, Low H et al (2012) Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 33:657–665PubMedCrossRef
19.
Terai K, Mizukami K, Okada M (2008) Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. Nephrology (Carlton) 13:139–146CrossRef
20.
Wang X, Collins HL, Ranalletta M et al (2007) Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117:2216–2224PubMedCrossRef
21.
Mukhamedova N, Escher G, D’Souza W et al (2008) Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 49:2312–2322PubMedCrossRef
22.
Folch J, Lees M, Sloane-Stanley GM (1957) A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509PubMed
23.
Coughlan MT, Thallas-Bonke V, Pete J et al (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148:886–895PubMedCrossRef
24.
Sviridov D, Fidge N (1995) Efflux of intracellular vs plasma membrane cholesterol in HepG2 cells: different availability and regulation by apolipoprotein A-I. J Lipid Res 36:1887–1896PubMed
25.
Christensen MM, Brasch-Andersen C, Green H et al (2011) The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 21:837–850PubMedCrossRef
26.
Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49:22–31PubMedCrossRef
27.
Shafrir E, Ziv E, Mosthaf L (1999) Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci 892:223–246PubMedCrossRef
28.
Yokozawa T, Zheng PD, Oura H, Koizumi F (1986) Animal model of adenine-induced chronic renal failure in rats. Nephron 44:230–234PubMedCrossRef
29.
Morishita Y, Ohnishi A, Watanabe M, Ishibashi K, Kusano E (2011) Establishment of acute kidney injury mouse model by 0.75% adenine ingestion. Ren Fail 33:1013–1018PubMedCrossRef
30.
Liang K, Kim CH, Vaziri ND (2005) HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 288:F539–F544PubMedCrossRef
31.
Nobecourt E, Tabet F, Lambert G et al (2010) Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 30:766–772PubMedCrossRef
32.
Isoda K, Folco EJ, Shimizu K, Libby P (2007) AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 192:298–304PubMedCrossRef
33.
Passarelli M, Tang C, McDonald TO et al (2005) Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54:2198–2205PubMedCrossRef
34.
Ohgami N, Nagai R, Miyazaki A et al (2001) Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 276:13348–13355PubMedCrossRef
35.
Zhou H, Tan KC, Shiu SW, Wong Y (2008) Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab Res Rev 24:617–623PubMedCrossRef
36.
Cavallero E, Brites F, Delfly B et al (1995) Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 15:2130–2135PubMedCrossRef
37.
Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK (1999) Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metabolism 48:139–143PubMedCrossRef
38.
Dullaart RP, Groen AK, Dallinga-Thie GM, de Vries R, Sluiter WJ, van Tol A (2008) Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. Eur J Endocrinol 158:53–60PubMedCrossRef
39.
de Vries R, Groen AK, Perton FG et al (2008) Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre [beta]-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 196:733–741PubMedCrossRef
40.
Moerland M, Samyn H, van Gent T et al (2007) Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J Lipid Res 48:2622–2631PubMedCrossRef
41.
Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR (2007) Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195:385–391PubMedCrossRef
42.
Matsuura F, Wang N, Chen W, Jiang X-C, Tall AR (2006) HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 116:1435–1442PubMedCrossRef
43.
Yvan-Charvet L, Matsuura F, Wang N et al (2007) Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 27:1132–1138PubMedCrossRef
44.
Francis GA, Oram JF, Heinecke JW, Bierman EL (1996) Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry 35:15188–15197PubMedCrossRef
45.
Matsuki K, Tamasawa N, Yamashita M et al (2009) Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis 206:434–438PubMedCrossRef
46.
Sviridov D, Hoang A, Ooi E, Watts G, Barrett PHR, Nestel P (2008) Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 197:732–739PubMedCrossRef
47.
Sharma K, McCue P, Dunn SR (2003) Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284:F1138–F1144PubMed
Metadata
Title
Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models
Authors
H. Low
A. Hoang
J. Forbes
M. Thomas
J. G. Lyons
P. Nestel
L. A. Bach
D. Sviridov
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2570-9

Other articles of this Issue 9/2012

Diabetologia 9/2012 Go to the issue

Short Communication

The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes

Letter

Renoprotective effects of renin–angiotensin–aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis. Reply to Catalá-López F [letter]

Article

SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes

Article

Mouse hypothalamic GT1-7 cells demonstrate AMPK-dependent intrinsic glucose-sensing behaviour

Article

Age at menarche and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study

Review

Adiponectin: mechanistic insights and clinical implications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits